Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma

Margaret A. Tempero, Anne Kessinger

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Ten patients with advanced ovarian carcinoma were treated with hexa‐methylmelamine and melphalan after failing first‐line combination chemotherapy. In eight patients residual disease was evident only at second‐look laparotomy. Surgical debulking was accomplished in four patients but only two patients had residual disease of less than 2 cm. Two of these four patients are alive without evidence of disease at 20 and 24 months. The remaining patients have expired (median survival 6 months). The combination of hexamethylmelamine and melphalan after surgical debulking at second‐look operation may improve the salvage of patients with advanced ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)159-161
Number of pages3
JournalJournal of Surgical Oncology
Issue number3
StatePublished - Nov 1982


  • hexamethylmelamine
  • melphalan
  • ovarian neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma'. Together they form a unique fingerprint.

Cite this